Adam Michael Howard, MD | |
3723 W 12600 S Ste 150, Riverton, UT 84065-7296 | |
(801) 285-4560 | |
Not Available |
Full Name | Adam Michael Howard |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 13 Years |
Location | 3723 W 12600 S Ste 150, Riverton, Utah |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063711463 | NPI | - | NPPES |
000000798136 | Other | IN | ANTHEM PIN |
201094910 | Medicaid | IN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 10536884-1205 (Utah) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Uncorrected refractive error (URE)-nearsightedness, farsightedness, and other focusing problems correctable by prescription lenses-is responsible for moderate to severe vision impairment in 101 million people and blindness in seven million people worldwide, reports a study in the March issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
A study led by researchers in the Oregon Health & Science University Smoking Cessation Center may change the way clinicians make treatment decisions for their patients who smoke.
Parents are tired and frustrated by current methods of discipline and punishment offered in books and media today. Parents understand that they are living in "The Discipline Trap," believing that discipline is something we do to our children rather than something we teach them.
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
› Verified 9 days ago
Entity Name | Ihc Health Services Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Uncorrected refractive error (URE)-nearsightedness, farsightedness, and other focusing problems correctable by prescription lenses-is responsible for moderate to severe vision impairment in 101 million people and blindness in seven million people worldwide, reports a study in the March issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
A study led by researchers in the Oregon Health & Science University Smoking Cessation Center may change the way clinicians make treatment decisions for their patients who smoke.
Parents are tired and frustrated by current methods of discipline and punishment offered in books and media today. Parents understand that they are living in "The Discipline Trap," believing that discipline is something we do to our children rather than something we teach them.
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Adam Michael Howard, MD Po Box 27128, Slc, UT 84127-0128 Ph: (801) 285-4560 | Adam Michael Howard, MD 3723 W 12600 S Ste 150, Riverton, UT 84065-7296 Ph: (801) 285-4560 |
News Archive
Uncorrected refractive error (URE)-nearsightedness, farsightedness, and other focusing problems correctable by prescription lenses-is responsible for moderate to severe vision impairment in 101 million people and blindness in seven million people worldwide, reports a study in the March issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
A study led by researchers in the Oregon Health & Science University Smoking Cessation Center may change the way clinicians make treatment decisions for their patients who smoke.
Parents are tired and frustrated by current methods of discipline and punishment offered in books and media today. Parents understand that they are living in "The Discipline Trap," believing that discipline is something we do to our children rather than something we teach them.
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
› Verified 9 days ago
Dr. Lindsay Malechek Klimes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3723 W 12600 S, Riverton, UT 84065 Phone: 801-507-4384 | |
Dr. Robert D Williams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1288 West 12700 South, Riverton, UT 84065 Phone: 801-253-0291 Fax: 801-446-2745 | |
Melanie Arrington, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 1420 W 12600 S Ste 102, Riverton, UT 84065 Phone: 801-254-4600 Fax: 801-254-9670 | |
Stephen B Devenport, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12391 S 4000 W, Riverton, UT 84065 Phone: 801-302-1760 Fax: 801-302-1714 | |
David W Brinton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3859 W 12600 S, Riverton, UT 84065 Phone: 801-302-7300 Fax: 801-302-7301 | |
Dr. Don Preston Allred, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1756 Park Ave, Riverton, UT 84065 Phone: 801-254-0309 Fax: 801-254-1012 |